Looking Into Watsco’s Recent Short Interest
Watsco’s (NYSE:WSO) short percent of float has fallen 7.01% since its last report. The company recently reported that…
How Is The Market Feeling About Faraday Future?
Faraday Future’s (NYSE:FFIE) short percent of float has fallen 67.02% since its last report. The company recently reported…
What 4 Analyst Ratings Have To Say About Bloomin Brands
In the preceding three months, 4 analysts have released ratings for Bloomin Brands (NASDAQ:BLMN), presenting a wide array…
How Is The Market Feeling About B&G Foods?
B&G Foods’s (NYSE:BGS) short percent of float has risen 20.4% since its last report. The company recently reported…
Ethereum Decreases More Than 3% Within 24 hours
Ethereum's (CRYPTO: ETH) price has decreased 3.25% over the past 24 hours to $3,794.60. This is contrary to the coins performance over the past week where it has experienced an up-trend of 2.0%, moving from $3,730.35 to its current price.
Amphenol Poised For Growth With AI Server Boom, Rising Copper Content, CIT Acquisition: Analyst
Citigroup analyst Asiya Merchant maintained Amphenol Corp with a Buy and raised the price target from $135 to $160.
Marvell Technology Q1 Earnings Preview: Investors ‘Particularly Interested’ In Company’s AI Business, Second Half Growth
Analysts see Marvell Technology having growth prospects for the latter half of 2024.
Arcturus Therapeutics’ Early Cystic Fibrosis Trial Results Encouraging – Analyst Cautiously Optimistic
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.
Nike Wins Partial Victory in Three-Stripe Trademark Battle with Adidas
Nike Inc. (NYSE: NKE) has won the right to feature three stripes on some trouser designs in Germany, following a significant court ruling. The Duesseldorf regional court partially overturned its previous decision, allowing Nike to use the stripes on four out of five disputed models. This decision comes amid an ongoing trademark dispute with Adidas AG (OTC
), highlighting the fierce competition in the sportswear industry.
With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.